利多卡因与奥昔布宁膀胱内缓释系统(TRG-100)治疗间质性膀胱炎/膀胱疼痛综合征、膀胱过度活动症及内镜术后留置输尿管支架患者的开放标签先导性安全性及有效性评估
这项开放标签、前瞻性先导研究纳入36例患者(间质性膀胱炎/膀胱疼痛综合征10例、膀胱过度活动症10例、内镜术后留置输尿管支架16例),评估膀胱内缓释系统TRG-100(利多卡因与奥昔布宁固定剂量复方)的安全性和有效性。结果显示各组疼痛及排尿症状指标均有统计学显著改善,作者认为TRG-100安全有效,但需进一步开展大规模随机对照试验评估。
要点
- 内镜术后留置输尿管支架组视觉模拟评分平均改善4分,变化有统计学意义。
- 膀胱过度活动症组排尿频率减少33.54%,变化有统计学意义。
- 间质性膀胱炎/膀胱疼痛综合征组视觉模拟评分平均改善3.2分、排尿频率减少25.43%、O'Leary Sant问卷评分平均降低8.1分,均具统计学意义。
核心结论
- 作者认为,在其研究人群中,膀胱内滴注TRG-100安全有效,可减轻疼痛及膀胱刺激症状。
- 作者提出,TRG-100的有效性和安全性应进一步通过大规模随机对照试验评估。
研究设计与样本
- 开放标签、前瞻性先导研究,共纳入36例患者:间质性膀胱炎/膀胱疼痛综合征10例、膀胱过度活动症10例、内镜术后留置输尿管支架16例。
- 内镜术后留置输尿管支架患者每周灌注一次直至拔除支架,膀胱过度活动症和间质性膀胱炎/膀胱疼痛综合征患者连续4周每周灌注。
- 疗效评估:内镜术后留置输尿管支架组采用视觉模拟评分,膀胱过度活动症组采用排尿日记,间质性膀胱炎/膀胱疼痛综合征组采用视觉模拟评分、排尿日记及O'Leary Sant问卷。
主要发现
- 内镜术后留置输尿管支架组视觉模拟评分平均改善4分,变化有统计学意义。
- 膀胱过度活动症组排尿频率减少33.54%,变化有统计学意义。
- 间质性膀胱炎/膀胱疼痛综合征组视觉模拟评分平均改善3.2分,排尿频率减少25.43%,O'Leary Sant问卷评分平均降低8.1分,所有变化均有统计学意义。
临床怎么用
- 作者认为TRG-100在其研究人群中安全有效,可减轻疼痛及膀胱刺激症状,并建议进一步开展大规模随机对照试验评估其有效性和安全性。
局限性
- 原文报告TRG-100的有效性和安全性需进一步通过大规模随机对照试验评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Intravesical instillation of analgesic and anticholinergic drugs have shown efficacy in the treatment of pain and voiding symptoms. Unfortunately, drug loss with urination and dilution in the bladder limit their durability and clinical usefulness. We have recently developed and tested in vitro, a sustained delivery system (TRG-100) of fixed-dose combination of lidocaine and oxybutynin designed to allow for a longer exposure of the urinary bladder to the drugs. OBJECTIVE: To asses the safety and efficacy of TRG-100 in Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS), overactive bladder (OAB), and endourological intervention stented (EUI) patients in an open-label, prospective study. METHODS: Thirty-six patients were enrolled: 10 IC/BPS, 10 OAB, and 16 EUI. EUI patients received a once-weekly installation until stent removal, OAB and IC/BPS patient received weekly installations for 4 consecutive weeks. Treatment effect was assessed by visual analog scale (VAS) score for the EUI group, voiding diaries for OAB group and VAS score, voiding diaries and O'Leary Sant Questionnaires for the IC/BPS group. RESULTS: The EUI group showed a mean 4-point improvement in their VAS score. The OAB group showed 33.54% reduction in frequency of urination and IC/PBS group showed a mean of 3.2-point improvement in their VAS score, 25.43% reduction in frequency of urination, and a mean 8.1-point reduction in O'Leary Sant Questionnaires score. All changes were statistically significant. CONCLUSION: Intravesical instillation of TRG-100 was found to be safe and efficient in reducing pain and irritative bladder symptoms in our study population. TRG-100 efficacy and safety should be further assessed in a large, randomized control trial.
引用
- Raisin G, Dothan D, Perez D, et al. Open Label, Pilot Evaluation of the Safety and Efficacy of Intravesical Sustained Release System of Lidocaine and Oxybutynin (TRG-100) for Patients With Interstitial Cystitis/Bladder Pain Syndrome, Overactive Bladder and Patients With Retained Ureteral Stents Following Endourological Interventions. Urology. 2023. PMID: 37268171. doi:10.1016/j.urology.2023.05.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。